Journal ArticleDOI
Intravitreale Implantate
TLDR
In this paper, Dexamethason-Implantate sind bereits fur die Therapie von retinalen Venenverschlussen zugelassen and werden hier erfolgreich eingesetzt.Abstract:
Fur die Therapie der nichtinfektiosen Uveitis werden Immunsuppressiva verwendet, sofern keine ausreichende Reiz- und Rezidivfreiheit mit Steroiden in niedriger Dosierung zu erreichen ist. Hierbei werden zum Erhalt des Visus auch bei Erkrankungen, die auf die Augen beschrankt sind, zum Teil erhebliche Nebenwirkungen in Kauf genommen. Wunschenswert ist also eine Therapie, die hochwirksam ist, auf die Augen beschrankt bleibt und ein geringes Nebenwirkungspotenzial aufweist. Hierzu wurden die Fluocinolon-acetonid- und Dexamethason-Implantate entwickelt. Dexamethason-Implantate sind bereits fur die Therapie von retinalen Venenverschlussen zugelassen und werden hier erfolgreich eingesetzt. Das diabetische Makulaodem ist ein weiteres mogliches Einsatzgebiet fur Dexamethason-Implantate.read more
Citations
More filters
Journal ArticleDOI
Simulation of drug distribution in the vitreous body after local drug application into intact vitreous body and in progress of posterior vitreous detachment.
Christian Loch,Malte Bogdahn,Sandra Stein,Stefan Nagel,Rudolf F. Guthoff,Werner Weitschies,Anne Seidlitz +6 more
TL;DR: The results indicate that convective forces may be of predominate influence on initial drug distribution and the impact of these forces on drug transport increases with simulated progression of PVD.
Journal ArticleDOI
Intravitreales Dexamethason-Implantat zur Behandlung des persistierenden postoperativen Makulaödems nach Vitrektomie
TL;DR: In this paper, the Wirksamkeit eines Dexamethason-Implantats zur Behandlung des persistierenden zystoiden Makulaodems (CMO) in vitrektomierten Augen was untersuchen.
References
More filters
Journal ArticleDOI
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
David M. Brown,Peter A. Campochiaro,Rishi P. Singh,Zhengrong Li,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid improvement in 6-month visual acuity and macular edema following CRVO, with low rates of ocular and nonocular safety events.
Journal ArticleDOI
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Julia A. Haller,Francesco Bandello,Rubens Belfort,Mark S. Blumenkranz,Mark C Gillies,Jeffrey S. Heier,Anat Loewenstein,Young-Hee Yoon,Marie-Louise Jacques,Jenny Jiao,Xiao-yan Li,Scott M. Whitcup +11 more
TL;DR: In this paper, the safety and efficacy of dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in eyes with vision loss due to macular edema (ME) associated with BRVO or central retinal vein occlusion (CRVO).
Journal ArticleDOI
Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel
Douglas A. Jabs,James T. Rosenbaum,C. Stephen Foster,Gary N. Holland,Glenn J. Jaffe,James S. Louie,Robert B. Nussenblatt,E. Richard Stiehm,Howard H. Tessler,Russell N. Van Gelder,Scott M. Whitcup,David E. Yocum +11 more
TL;DR: A 12-person panel of physicians with expertise in ophthalmologic, pediatric, and rheumatologic disease, in research, and in the use of immunosuppressive drugs in patient care was formed in 1999 to provide recommendations for the use in the treatment of patients with ocular inflammatory disorders as discussed by the authors.
Journal ArticleDOI
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion
Peter A. Campochiaro,Jeffrey S. Heier,Leonard Feiner,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Wendy Yee Murahashi,Roman G. Rubio +7 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO with low rates of ocular and nonocular safety events and no new safety events were identified in patients with BRVO.
Journal ArticleDOI
Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
Glenn J. Jaffe,Daniel F. Martin,David Callanan,P. Andrew Pearson,Brian Levy,Brian Levy,Timothy L. Comstock +6 more
TL;DR: The FA implant significantly reduced uveitis recurrences, improved VA, and decreased the need for adjunctive therapy in the studied patient population.